Xeris Pharmaceuticals | XERS - Ebitda


Xeris Pharmaceuticals reported $17.42M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Celltrion KRW 374.56B 352.67B Sep/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.88B 1.59B Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 15.51M 3.39M Jun/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Neuren Pharmaceuticals AUD 176.7M 166.79M Dec/2024
Organigram Holdings CAD 6.15M 455K Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pharma Mar EUR -1.98M 28.13M Sep/2025
Qiagen NV USD 193.17M 15.81M Sep/2025
Sartorius EUR 277.4M 30.5M Dec/2025
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025
Tilray USD 8.36M 1.82M Sep/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 531.61M 658.23M Jun/2025